N-Acetyl-L-asparaginol
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Category | Others |
Catalog number | BBF-05185 |
CAS | 38922-66-6 |
Molecular Weight | 160.17 |
Molecular Formula | C6H12N2O3 |
Purity | >95% by HPLC |
Online Inquiry
Specification
Synonyms | Butanamide, 3-(acetylamino)-4-hydroxy-, (S)-; (S)-3-acetamido-4-hydroxybutanamide |
Storage | Store at -20°C |
IUPAC Name | (3S)-3-Acetamido-4-hydroxybutanamide |
Canonical SMILES | CC(=O)N[C@@H](CC(=O)N)CO |
InChI | InChI=1S/C6H12N2O3/c1-4(10)8-5(3-9)2-6(7)11/h5,9H,2-3H2,1H3,(H2,7,11)(H,8,10)/t5-/m0/s1 |
InChI Key | SZIGYWHQDBBFJW-YFKPBYRVSA-N |
Properties
Boiling Point | 549.5±45.0°C at 760 mmHg |
Density | 1.2±0.1 g/cm3 |
Reference Reading
1. Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy
Heng-Huan Lee, Ying-Nai Wang, Weiya Xia, Chia-Hung Chen, Kun-Ming Rau, Leiguang Ye, Yongkun Wei, Chao-Kai Chou, Shao-Chun Wang, Meisi Yan, Chih-Yen Tu, Te-Chun Hsia, Shu-Fen Chiang, K S Clifford Chao, Ignacio I Wistuba, Jennifer L Hsu, Gabriel N Hortobagyi, Mien-Chie Hung Cancer Cell. 2019 Aug 12;36(2):168-178.e4. doi: 10.1016/j.ccell.2019.06.008. Epub 2019 Jul 18.
Reactivation of T cell immunity by PD-1/PD-L1 immune checkpoint blockade has been shown to be a promising cancer therapeutic strategy. However, PD-L1 immunohistochemical readout is inconsistent with patient response, which presents a clinical challenge to stratify patients. Because PD-L1 is heavily glycosylated, we developed a method to resolve this by removing the glycan moieties from cell surface antigens via enzymatic digestion, a process termed sample deglycosylation. Notably, deglycosylation significantly improves anti-PD-L1 antibody binding affinity and signal intensity, resulting in more accurate PD-L1 quantification and prediction of clinical outcome. This proposed method of PD-L1 antigen retrieval may provide a practical and timely approach to reduce false-negative patient stratification for guiding anti-PD-1/PD-L1 therapy.
2. Fucosyltransferases produce N-glycans containing core l-galactose
Hiroyuki Ohashi, Takao Ohashi, Hiroyuki Kajiura, Ryo Misaki, Shinichi Kitamura, Kazuhito Fujiyama Biochem Biophys Res Commun. 2017 Jan 29;483(1):658-663. doi: 10.1016/j.bbrc.2016.12.087. Epub 2016 Dec 18.
l-Galactose (l-Gal) containing N-glycans and cell wall polysaccharides have been detected in the l-Fuc deficient mur1 mutant of Arabidopsis thaliana. The l-Gal residue is thought to be transferred from GDP-l-Gal, which is a structurally related analog of GDP-l-Fuc, but in vitrol-galactosylation activity has never been detected. In this study, we carried out preparative scale GDP-l-Gal synthesis using recombinant A. thaliana GDP-mannose-3',5'-epimerase. We also demonstrated the l-galactosylation assay of mouse α1,6-fucosyltransferase (MmFUT8) and A. thaliana α1,3-fucosyltransferase (AtFucTA). Both fucosyltransferases showed l-galactosylation activity from GDP-l-Gal to asparagine-linked N-acetyl-β-d-glucosamine of asialo-agalacto-bi-antennary N-glycan instead of l-fucosylation. In addition, the apparent Km values of MmFUT8 and AtFucTA suggest that l-Fuc was preferentially transferred to N-glycan compared with l-Gal by fucosyltransferases. Our results clearly demonstrate that MmFUT8 and AtFucTA transfer l-Gal residues from GDP-l-Gal and synthesize l-Gal containing N-glycan in vitro.
3. Keratan Sulphate in the Tumour Environment
Anthony J Hayes, James Melrose Adv Exp Med Biol. 2020;1245:39-66. doi: 10.1007/978-3-030-40146-7_2.
Keratan sulphate (KS) is a bioactive glycosaminoglycan (GAG) of some complexity composed of the repeat disaccharide D-galactose β1→4 glycosidically linked to N-acetyl glucosamine. During the biosynthesis of KS, a family of glycosyltransferase and sulphotransferase enzymes act sequentially and in a coordinated fashion to add D-galactose (D-Gal) then N-acetyl glucosamine (GlcNAc) to a GlcNAc acceptor residue at the reducing terminus of a nascent KS chain to effect chain elongation. D-Gal and GlcNAc can both undergo sulphation at C6 but this occurs more frequently on GlcNAc than D-Gal. Sulphation along the developing KS chain is not uniform and contains regions of variable length where no sulphation occurs, regions which are monosulphated mainly on GlcNAc and further regions of high sulphation where both of the repeat disaccharides are sulphated. Each of these respective regions in the KS chain can be of variable length leading to KS complexity in terms of chain length and charge localization along the KS chain. Like other GAGs, it is these variably sulphated regions in KS which define its interactive properties with ligands such as growth factors, morphogens and cytokines and which determine the functional properties of tissues containing KS. Further adding to KS complexity is the identification of three different linkage structures in KS to asparagine (N-linked) or to threonine or serine residues (O-linked) in proteoglycan core proteins which has allowed the categorization of KS into three types, namely KS-I (corneal KS, N-linked), KS-II (skeletal KS, O-linked) or KS-III (brain KS, O-linked). KS-I to -III are also subject to variable addition of L-fucose and sialic acid groups. Furthermore, the GlcNAc residues of some members of the mucin-like glycoprotein family can also act as acceptor molecules for the addition of D-Gal and GlcNAc residues which can also be sulphated leading to small low sulphation glycoforms of KS. These differ from the more heavily sulphated KS chains found on proteoglycans. Like other GAGs, KS has evolved molecular recognition and information transfer properties over hundreds of millions of years of vertebrate and invertebrate evolution which equips them with cell mediatory properties in normal cellular processes and in aberrant pathological situations such as in tumourogenesis. Two KS-proteoglycans in particular, podocalyxin and lumican, are cell membrane, intracellular or stromal tissue-associated components with roles in the promotion or regulation of tumour development, mucin-like KS glycoproteins may also contribute to tumourogenesis. A greater understanding of the biology of KS may allow better methodology to be developed to more effectively combat tumourogenic processes.
Recommended Products
BBF-05827 | Spliceostatin A | Inquiry |
BBF-01829 | Deoxynojirimycin | Inquiry |
BBF-04609 | 1,1-Dimethylbiguanide hydrochloride | Inquiry |
BBF-05886 | Notoginsenoside R1 | Inquiry |
BBF-00693 | Ansamitocin P-3 | Inquiry |
BBF-03915 | Clavulanate Potassium (1:1 mixture with silicon dioxide) | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳